2TK

ELEDON PHARMACEUT.DL-001

Healthcare · EUR · F

2TK

Price

€3.245

+0.87%

Cap

€299.49M

Earnings

30d Trend

-1.9%

2TK
Loading chart data...
0 days · % change from startPowered by Brain47
VolatilityHigh

67% annualised over 90 days

BRAIN47 SIGNAL

0
MODERATE
Risk Level85
Quality47
Momentum69
Technical59
Fundamentals50

Raw weighted: 52×Macro 0.99 (1%)=51

RISK

85/100
90d Volatility
67.4%High
ATR %
5.6%High daily moves
Max Drawdown (1Y)
-68.1%Volatile

QUALITY

47/100
ROE (avg)
-56.3%*Negative
Debt/Equity
0.00Low leverage

MOMENTUM

69/100
12-1M Momentum
+11.7%Strong uptrend
6-1M Momentum
+127.2%Positive
1M Return
+12.1%Strong recent gains
Relative Strength
+0.3% vs sectorIn-line

TECHNICAL

59/100
RSI (14)
59.3Neutral
Price vs SMA200
+47.2%Bullish trend
MACD
-0.02Bearish momentum
Bollinger Band
69%Mid-range
SMA Cross
Death CrossDeath Cross
Trend Quality (KER)
0.263Noisy/choppy

FUNDAMENTALS

50/100

Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%

Running historical backtest...

BRAIN47 HORIZON ANALYSIS

<3 months54
3-12 months80
1-5+ years48

6-9 month momentum thesis — strong trend with confirmation

BRAIN47'S ASSESSMENT

I rate ELEDON PHARMACEUT.DL-001 at 51/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 69/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.

PAST PERFORMANCE

1 MONTH

+12.1%

3 MONTHS

+48.9%

12 MONTHS

+23.8%

Trailing returns — past performance, not a projection.

DETAILED ANALYSIS

6-9 month momentum thesis — strong trend with confirmation. Momentum (69) and Technical (59) are the primary strengths. I note an elevated risk profile — this warrants closer monitoring. Historical volatility is elevated at 67%. I classify this as a growth position — strong momentum combined with growth potential points to capital appreciation.

growthScore: 51/100

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.